Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2013
11/12/2013US8580266 Immune modulation via C-type lectin
11/12/2013US8580265 Antibody molecules which bind IL-17A and IL-17F
11/12/2013US8580264 Subcutaneously administered anti-IL-6 receptor antibody
11/12/2013US8580262 Group B Streptococcus antigens
11/12/2013US8580261 Methods for prevention and treatment of inflammation using anti-chemokine antibodies
11/12/2013US8580260 Method of using anti-IL-13 antibodies
11/12/2013US8580259 Human monoclonal antibodies to BTLA and methods of use
11/12/2013US8580258 Treatment of tumors using specific anti-L1 antibody
11/12/2013US8580257 Antibodies that specifically block the biological activity of kidney associated antigen 1 (KAAG1)
11/12/2013US8580256 Stabilized anti-hepatitis B (HBV) antibody formulations
11/12/2013US8580255 Method for the treatment of rheumatoid arthritis using a TLR2 antagonistic antibody
11/12/2013US8580254 Anti-IGF antibodies
11/12/2013US8580253 Immunomodulating compositions and methods of use
11/12/2013US8580247 PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
11/12/2013DE202005022108U1 Influenza-Virus-Impfstoffe Influenza virus vaccines
11/12/2013CA2782511C Circulation of components during homogenization of emulsions
11/12/2013CA2714357C Mutations in neuronal gene sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
11/12/2013CA2604362C Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation
11/12/2013CA2549652C Cd40 antibody formulation and methods
11/12/2013CA2532173C Antibodies against insulin-like growth factor i receptor and uses thereof
11/12/2013CA2522331C Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
11/12/2013CA2515474C Antibody molecules having specificity for human il-1.beta.
11/12/2013CA2493142C Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers
11/12/2013CA2477012C Anti-a.beta. antibodies and their use
11/12/2013CA2471924C Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases, and for modulation of cell survival and/or death
11/12/2013CA2448022C Compositions for protein delivery via the pulmonary route
11/12/2013CA2447274C Heterologous protection induced by immunization with invaplex vaccine
11/12/2013CA2409813C Compositions and methods for treatment of mucosal infections
11/12/2013CA2342376C A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
11/12/2013CA2213451C Generation of human cytotoxic t-cells specific for carcinoma self-associated antigens and uses thereof
11/07/2013WO2013166470A2 Uses of cxcl17, a novel chemokine marker of human lung and gastrointestinal disease
11/07/2013WO2013166453A2 T cell epitopes from cockroach and methods of making and using same
11/07/2013WO2013166448A1 Stable formulations containing anti-pcsk9 antibodies
11/07/2013WO2013166290A1 P21 biomarker assay
11/07/2013WO2013166236A1 Human antibodies to fel d1 and methods of use thereof
11/07/2013WO2013166183A2 Replikin sequences and their antibodies for diagnostics, therapeutics, and vaccines against prion and neurodegenerative disorders including alzheimer's disease
11/07/2013WO2013166156A2 Compositions and methods for treating or preventing osteoarthritis
11/07/2013WO2013166110A1 Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
11/07/2013WO2013166099A1 Novel antibodies
11/07/2013WO2013166030A2 Detecting complement activation
11/07/2013WO2013165791A1 Anti-il-23p19 antibodies
11/07/2013WO2013165690A1 Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
11/07/2013WO2013165613A1 Methods of treating and preventing staphylococcus aureus infections and associated conditions
11/07/2013WO2013165593A1 COMPOSITIONS AND METHODS FOR β-GLUCAN IMMUNOTHERAPY
11/07/2013WO2013165592A1 Treatment of latent hiv infection
11/07/2013WO2013165590A1 Methods for treating idiopathic pulmonary fibrosis
11/07/2013WO2013164837A1 Pharmaceutical formulations of tnf-alpha antibodies
11/07/2013WO2013164754A2 Prostate-associated antigens and vaccine-based immunotherapy regimens
11/07/2013WO2013164359A1 Combination vaccine for the treatment of leishmaniasis
11/07/2013WO2013164357A1 Compositions
11/07/2013WO2013164355A1 Compositions
11/07/2013WO2013164354A1 Composition
11/07/2013WO2013164334A1 Escherichia coli vaccine
11/07/2013WO2013163893A1 Modified bacteria and uses thereof for treatment of cancer or tumor
11/07/2013WO2013163689A1 Vaccine and uses thereof
11/07/2013WO2013152352A8 Live, attenuated rubella vector to express vaccine antigens
11/07/2013WO2013119170A3 Prevention of inflammatory disorders in domestic non-human mammals
11/07/2013WO2013114112A3 Stabilized aqueous antibody compositions
11/07/2013WO2013110818A3 Immunogens for hiv vaccination
11/07/2013WO2013084071A3 Clostridium difficile toxin-based vaccine
11/07/2013WO2012145507A3 Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
11/07/2013WO2012140620A8 Compositions for preventing and/or treating an infection by an hiv-1 virus
11/07/2013WO2012135740A3 Cd37-binding molecules and immunoconjugates thereof
11/07/2013WO2002083860A9 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
11/07/2013US20130296541 Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions
11/07/2013US20130296249 Methods of blocking tissue destruction by autoreactive t cells
11/07/2013US20130295610 Chimeric antigens for eliciting an immune response
11/07/2013US20130295589 Ngal for diagnosis of renal conditions
11/07/2013US20130295167 Enhanced immune response in bovine species
11/07/2013US20130295165 Compositions and methods for treating viral infections
11/07/2013US20130295164 Method for adjuvanting lipopolysaccharide (LPS) of Gram-negative bacteria
11/07/2013US20130295162 Flavivirus domain iii vaccine
11/07/2013US20130295147 Gas-filled microvesicles for use as vaccine
11/07/2013US20130295140 Testosterone olfaction
11/07/2013US20130295139 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
11/07/2013US20130295138 Roadmap for controlling malaria
11/07/2013US20130295137 Compositions And Methods For Treatment Of Microbial Infections
11/07/2013US20130295136 Live attenuated catfish vaccine and method of making
11/07/2013US20130295135 FUNCTIONAL INFLUENZA VIRUS LIKE PARTICLES (VLPs)
11/07/2013US20130295134 Recombinant bicistronic flavivirus vectors
11/07/2013US20130295133 Recombinant virus expressing foreign dna encoding feline cd80, feline cd86, feline cd28, or feline ctla-4 and uses thereof
11/07/2013US20130295132 Conjugation of Streptococcal Capsular Saccharides
11/07/2013US20130295131 Generation of antigenic virus-like particles through protein-protein linkages
11/07/2013US20130295129 Immunostimulatory compositions and methods of use thereof
11/07/2013US20130295128 Chimeric vaccines
11/07/2013US20130295127 Vaccine against clostridium perfringens
11/07/2013US20130295126 Vaccines for inclusion body hepatitis
11/07/2013US20130295124 Orf7 deficient varicella virus, vaccine comprising the virus and use thereof
11/07/2013US20130295123 Vaccine comprising amb a 1 peptides for use in the treatment of ragweed allergy
11/07/2013US20130295122 Elastin digest compositions and methods utilizing same
11/07/2013US20130295121 Covalent Diabodies and Uses Thereof
11/07/2013US20130295119 Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
11/07/2013US20130295117 Aldosterone induced elastin production
11/07/2013US20130295114 PVRL4 (Nectin4) is a Receptor for Measles Virus
11/07/2013US20130295111 Methods and compositions for treating disorders associated with hyperactive immune system
11/07/2013US20130295110 Prostate-associated antigens and vaccine-based immunotherapy regimens
11/07/2013US20130295106 Frizzled-Binding Agents And Uses Thereof
11/07/2013US20130295105 Frizzled-binding agents and uses thereof
11/07/2013US20130295102 Compositions and methods for antibodies targeting factor p
11/07/2013US20130295099 N-linkedglycan compounds
1 ... 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 ... 1823